{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:47:46Z","timestamp":1788410866935,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ejca.2014.09.003","type":"journal-article","created":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T11:55:14Z","timestamp":1412164514000},"page":"3003-3010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions"],"prefix":"10.1016","volume":"50","author":[{"given":"Ingvild L\u00f8berg","family":"Tangen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrica M.J.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari K.","family":"Halle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanthida","family":"Kusonmano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jone","family":"Trovik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling A.","family":"Hoivik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Krakstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga B.","family":"Salvesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2014.09.003_b0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(12)70213-9","article-title":"Markers for individualised therapy in endometrial carcinoma","volume":"13","author":"Salvesen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.003_b0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2014.09.003_b0015","doi-asserted-by":"crossref","first-page":"e009","DOI":"10.1621\/nrs.07009","article-title":"Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression","volume":"7","author":"Scarpin","year":"2009","journal-title":"Nucl Recept Signal"},{"issue":"6","key":"10.1016\/j.ejca.2014.09.003_b0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrc3518","article-title":"Progesterone signalling in breast cancer: a neglected hormone coming into the limelight","volume":"13","author":"Brisken","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.003_b0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/1055-9965.98.14.1","article-title":"Endogenous hormones and ovarian cancer: epidemiology and current hypotheses","volume":"14","author":"Lukanova","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.003_b0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tem.2011.01.005","article-title":"Progesterone: the ultimate endometrial tumor suppressor","volume":"22","author":"Yang","year":"2011","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ejca.2014.09.003_b0035","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.003_b0040","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.756","article-title":"Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study","volume":"110","author":"Purdie","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.003_b0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/gyno.1998.5023","article-title":"Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma","volume":"69","author":"Fukuda","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.003_b0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0090-8258(90)90012-A","article-title":"Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance","volume":"38","author":"Kleine","year":"1990","journal-title":"Gynecol Oncol"},{"issue":"9484","key":"10.1016\/j.ejca.2014.09.003_b0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2014.09.003_b0060","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose\u2013response study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.003_b0065","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2","article-title":"Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature","volume":"79","author":"Kim","year":"1997","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.003_b0070","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/humrep\/dei434","article-title":"Long-term conservative therapy for endometrial adenocarcinoma in young women","volume":"21","author":"Yahata","year":"2006","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.003_b0075","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1525-1438.2007.00897.x","article-title":"Hormone therapy in advanced and recurrent endometrial cancer: a systematic review","volume":"17","author":"Decruze","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.003_b0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/gyno.1993.1211","article-title":"Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients","volume":"50","author":"Kadar","year":"1993","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2014.09.003_b0085","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1158\/1078-0432.CCR-10-2412","article-title":"Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer","volume":"17","author":"Trovik","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2014.09.003_b0090","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2004.09.034","article-title":"Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer","volume":"22","author":"Stefansson","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.003_b0095","doi-asserted-by":"crossref","first-page":"543.e1","DOI":"10.1016\/j.ajog.2008.04.043","article-title":"GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival","volume":"199","author":"Engelsen","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.003_b0100","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.1999.17.5.1382","article-title":"Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study","volume":"17","author":"Salvesen","year":"1999","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2014.09.003_b0105","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/bjc.2012.91","article-title":"Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer patients with poor outcome","volume":"106","author":"Krakstad","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.003_b0110","doi-asserted-by":"crossref","first-page":"e98069","DOI":"10.1371\/journal.pone.0098069","article-title":"Switch in FOXA1 status associates with endometrial cancer progression","volume":"9","author":"Tangen","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.003_b0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12014-010-9055-y","article-title":"A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers","volume":"6","author":"Hennessy","year":"2010","journal-title":"Clin Proteomics"},{"issue":"7456","key":"10.1016\/j.ejca.2014.09.003_b0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.003_b0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5795","key":"10.1016\/j.ejca.2014.09.003_b0130","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.ejca.2014.09.003_b0135","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2014.09.003_b0140","first-page":"7926","article-title":"Hormonal therapy in advanced or recurrent endometrial cancer","volume":"12","author":"Kokka","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.ejca.2014.09.003_b0145","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","author":"Lindstrom","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.003_b0150","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/j.1460-2075.1990.tb08280.x","article-title":"Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B","volume":"9","author":"Kastner","year":"1990","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.ejca.2014.09.003_b0155","first-page":"1860","article-title":"Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action","volume":"58","author":"Kumar","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2014.09.003_b0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.1997.tb48520.x","article-title":"Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation","volume":"828","author":"Leslie","year":"1997","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.ejca.2014.09.003_b0165","first-page":"1244","article-title":"Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function","volume":"7","author":"Vegeto","year":"1993","journal-title":"Mol Endocrinol"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.003_b0170","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/MCB.15.4.1847","article-title":"Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors","volume":"15","author":"Kraus","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.003_b0175","first-page":"447","article-title":"PCNA immunostaining as a valid alternative to tritiated thymidine-autoradiography to detect proliferative cell fraction in transitional cell bladder carcinomas","volume":"14","author":"Lavezzi","year":"2000","journal-title":"In Vivo"},{"issue":"8","key":"10.1016\/j.ejca.2014.09.003_b0180","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19930415)71:8<2448::AID-CNCR2820710804>3.0.CO;2-V","article-title":"Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy","volume":"71","author":"Yonemura","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.003_b0185","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.4317\/medoral.18573","article-title":"Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors","volume":"18","author":"Bologna-Molina","year":"2013","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.003_b0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1525-1438.2006.00279.x","article-title":"Growth regulation and transcriptional activities of estrogen and progesterone in human endometrial cancer cells","volume":"16","author":"Gielen","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.003_b0195","first-page":"502","article-title":"Physiological action of progesterone in target tissues","volume":"18","author":"Graham","year":"1997","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.003_b0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1210\/edrv-11-2-266","article-title":"Progestin regulation of cellular proliferation","volume":"11","author":"Clarke","year":"1990","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.003_b0205","first-page":"881","article-title":"Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors","volume":"62","author":"Dai","year":"2002","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.003_b0210","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/IGC.0b013e3182169239","article-title":"Adjuvant chemotherapy for endometrial cancer","volume":"21","author":"Tangjitgamol","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.003_b0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2007.10.012","article-title":"CDK inhibitors in cancer therapy: what is next?","volume":"29","author":"Malumbres","year":"2008","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.003_b0220","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2005.05.017","article-title":"A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study","volume":"98","author":"Grendys","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2014.09.003_b0225","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/annonc\/mds045","article-title":"Results of a randomized phase 2 study of Pd 0332991, a cyclin-dependent kinase (Cdk) 4\/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of Er +\/Her2-advanced breast cancer (Bc)","volume":"23","author":"Finn","year":"2012","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914009381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914009381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T23:33:23Z","timestamp":1689550403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914009381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":45,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0959804914009381"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.09.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}